iOnctura is a clinical-stage biotech developing selective cancer therapies against targets that play critical roles in multiple tumor survival pathways such as cellular proliferation; escape from immune detection; and drug resistance. iOnctura’s pioneering approach to drug development is expected to offer significant clinical benefits over the traditional approach of targeting a single pathway alone. iOnctura has progressed two therapeutic candidates into mid-stage clinical development: IOA-244, a highly selective allosteric inhibitor of PI3Kδ to treat Treg-driven tumors; and IOA-289, a highly selective, non-competitive autotaxin (ATX) inhibitor to treat cancer associated fibroblast (CAF) driven tumors. iOnctura is backed by specialist institutional investors including M Ventures, Inkef Capital, VI Partners, Schroders Capital, and 3B Future Health Fund. For more information, please visit www.ionctura.com
View Top Employees from iOncturaWebsite | http://www.ionctura.com |
Revenue | $608000 |
Employees | 22 (17 on RocketReach) |
Founded | 2017 |
Address | 15 Park Ave Sécheron, Geneva, Geneva 1202, CH |
Technologies |
JavaScript,
HTML,
Google Analytics
+9 more
(view full list)
|
Industry | Biotechnology Research, Business Services General, Biotechnology, Business Services, Science and Engineering |
SIC | SIC Code 873 Companies, SIC Code 87 Companies |
NAICS | NAICS Code 541 Companies, NAICS Code 5417 Companies, NAICS Code 541714 Companies, NAICS Code 54171 Companies, NAICS Code 54 Companies |
Looking for a particular iOnctura employee's phone or email?
The iOnctura annual revenue was $608000 in 2024.
Michael L is the Chief Medical Officer of iOnctura.
17 people are employed at iOnctura.
iOnctura is based in Geneva, Geneva.
The NAICS codes for iOnctura are [541, 5417, 541714, 54171, 54].
The SIC codes for iOnctura are [873, 87].